It is a PTM that regulates cardiovascular disease.78 O‐GlcNAcylation induced by high glucose is essential for the progression of cardiac hypertrophy via increased expression of ERK1/2 and cyclin D2.79 The activation of AMPK pathway inhibits cardiac hypertrophy by reducing O‐GlcNAcylation in vivo.80 Global cardiac protein O‐GlcNAc signalling is increased in various aetiologies of cardiac hypertrophy and failure.81 Here, MAPK3 is linked to cardiac hypertrophy.